-- FactSetが調査したアナリストによると、Cameco（CCJ）の平均投資判断は「オーバーウェイト」、平均目標株価は129.56ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Related Articles
Australia
BofA Adjusts Price Target on Pool to $226 From $229
Pool (POOL) has an average rating of overweight and mean price target of $262.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $228.70, Change: $+1.08, Percent Change: +0.47%
$POOL
Australia
BofA Adjusts Price Target on SiteOne Landscape Supply to $167 From $182
SiteOne Landscape Supply (SITE) has an average rating of overweight and mean price target of $169.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $142.26, Change: $-2.10, Percent Change: -1.45%
$SITE
Australia
Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility
Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%
$GILD$RCUS